Literature DB >> 23674070

Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.

Jun Yu1, Jeanne Drisko, Qi Chen.   

Abstract

Lack of effective therapy is a major problem in the treatment of pancreatic cancer. In the present study, we investigated a natural product, the extract of Pao Pereira (Pao), for its anti-pancreatic cancer effect in vitro and in vivo, either alone or in combination with the first-line chemotherapeutic drug gemcitabine (Gem). Pao induced dose-dependent apoptosis to all five tested pancreatic cancer cell lines. The combination of Pao and Gem had a synergistic effect in the inhibition of cell growth, with combination indices (CIs) <1 by Chou-Talalay's median effect analysis based on the isobologram principle. Adding Pao to Gem treatment reduced the concentration of Gem to produce an equitoxic effect on pancreatic cancer cells. In an orthotopic pancreatic xenograft mouse model, mice bearing PACN-1 tumors were treated with Pao and Gem, either alone or in combination. The progression of tumors was monitored longitudinally by imaging of live animals. While Gem did not provide significant inhibition, Pao treatment significantly suppressed tumor growth by 70-72%. Combined Pao and Gem treatment further enhanced the tumor inhibitory effect compared to Gem alone, and markedly reduced metastatic lesions in the peritoneum. Collectively, these data suggest that the extract of Pao possesses anti-pancreatic cancer activity and can enhance the effects of Gem in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23674070     DOI: 10.3892/or.2013.2461

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Identifying and Implementing Endpoints for Geriatric Mice.

Authors:  Linda A Toth
Journal:  Comp Med       Date:  2018-11-28       Impact factor: 0.982

Review 2.  Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.

Authors:  John K Triantafillidis; Eleni Triantafyllidi; Michail Sideris; Theodoros Pittaras; Apostolos E Papalois
Journal:  Nutrients       Date:  2022-01-30       Impact factor: 5.717

Review 3.  Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.

Authors:  Qingxi Yue; Guogang Gao; Gangyong Zou; Haiqing Yu; Xi Zheng
Journal:  Biomed Res Int       Date:  2017-01-23       Impact factor: 3.411

4.  Extract of the Medicinal Plant Pao Pereira Inhibits Pancreatic Cancer Stem-Like Cell In Vitro and In Vivo.

Authors:  Ruochen Dong; Ping Chen; Qi Chen
Journal:  Integr Cancer Ther       Date:  2018-07-09       Impact factor: 3.279

5.  Impact of ethanolic extract of Equisetum arvense (EA1) on pancreatic carcinoma AsPC-1 cells.

Authors:  Ajaz Ali Bhat; Bilal Ahamad; Muneeb U Rehman; Parvaiz Ahmad
Journal:  Saudi J Biol Sci       Date:  2020-01-30       Impact factor: 4.219

6.  Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase.

Authors:  Jiakuan Liu; Tian Fang; Meiqian Li; Yuting Song; Junzun Li; Zesheng Xue; Jiaxuan Li; Dandan Bu; Wei Liu; Qinghe Zeng; Yidan Zhang; Shifeng Yun; Ruimin Huang; Jun Yan
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

7.  Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice.

Authors:  Syed Umar Faruq Syed Najmuddin; Zahiah Mohamed Amin; Sheau Wei Tan; Swee Keong Yeap; Jeevanathan Kalyanasundram; Abhimanyu Veerakumarasivam; Soon Choy Chan; Suet Lin Chia; Khatijah Yusoff; Noorjahan Banu Alitheen
Journal:  PeerJ       Date:  2020-12-08       Impact factor: 2.984

8.  Extracts of the Medicinal Plants Pao Pereira and Rauwolfia vomitoria Inhibit Ovarian Cancer Stem Cells In Vitro.

Authors:  Ping Chen; Ruochen Dong; Qi Chen
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

9.  Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling.

Authors:  Yu Dong; Jiakuan Liu; Zesheng Xue; Jingya Sun; Zhengnan Huang; Yifeng Jing; Bangmin Han; Bing Shen; Jun Yan; Ruimin Huang
Journal:  BMC Complement Med Ther       Date:  2020-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.